Exscientia is a biotech company that combines the power of AI and human creativity to make safer and more sophisticated drugs available to all.
Exscientia is the world leader in developing and applying AI approaches specifically to design new and better therapeutic molecules in a faster and more cost-effective manner.
Exscientia was founded in 2012 by Andrew Hopkins. The company is headquartered in Oxford, Oxfordshire, United Kingdom, with an office in Dundee.
Exscientia aims to make safer, more sophisticated drugs available to all - more quickly and efficiently than ever before.
Exscientia's AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. It is the first company to automate drug design, surpassing conventional human endeavour.
Exscientia is currently working on a joint initiative to identify COVID-19 antiviral treatments with Diamond Light Source and Scripps Research, as well as a ground-breaking collaboration with SRI International to combine fully automated synthetic chemistry with AI.
Exscientia is backed by Novo Holdings, Evotec, Bristol Myers Squibb, GT Healthcare Capital Partners and others. The company raised $60M in Series C round on May 27, 2020. This brings Exscientia's total funding to $103.7M to date.